Equities

Assertio Holdings Inc

ASRT:NAQ

Assertio Holdings Inc

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)0.9657
  • Today's Change0.016 / 1.65%
  • Shares traded743.94k
  • 1 Year change-18.85%
  • Beta0.8244
Data delayed at least 15 minutes, as of Nov 21 2024 21:00 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Assertio Holdings, Inc. is a commercial pharmaceutical company offering differentiated products to patients. The Company has built its commercial portfolio through acquisition or licensing of approved products. Its comprehensive commercial capabilities include marketing through both a sales force and a non-personal promotion model, market access through payor contracting and trade and distribution. The Company’s primary marketed products include ROLVEDONTM (eflapegrastim-xnst) injection for subcutaneous use, INDOCIN (indomethacin) Suppositories, INDOCIN (indomethacin) Oral Suspension, Sympazan (clobazam) oral film, Otrexup (methotrexate) injection for subcutaneous use, SPRIX (ketorolac tromethamine) Nasal Spray, CAMBIA (diclofenac potassium for oral solution) and Zipsor (diclofenac potassium) Liquid filled capsules. INDOCIN (indomethacin) Suppositories and INDOCIN (indomethacin) Oral Suspension products are nonsteroidal anti-inflammatory drugs (NSAID).

  • Revenue in USD (TTM)125.76m
  • Net income in USD-68.49m
  • Incorporated2020
  • Employees53.00
  • Location
    Assertio Holdings Inc100 S. Saunders Road, Suite 300LAKE FOREST 60045United StatesUSA
  • Phone+1 (224) 419-7106
  • Fax+1 (302) 636-5454
  • Websitehttps://www.assertiotx.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
bluebird bio Inc53.12m-300.52m57.77m375.00------1.09-1.84-1.840.3039-0.02980.09852.034.42141,653.30-55.72-34.75-96.37-40.84-43.49-124.35-565.74-5,770.410.3272-13.371.03--720.04-11.588.00---30.47--
OptiNose Inc75.67m-31.15m59.56m132.00------0.787-0.2216-0.22160.5416-0.27250.65120.76592.96573,272.80-26.80-48.25---98.9590.2186.96-41.16-131.660.7198-1.611.48---6.9358.6452.58---27.96--
Cellectar Biosciences Inc0.00-49.67m64.10m20.00--41.37-----1.67-1.670.000.40790.00----0.00-168.84-83.69-450.38-99.80------------0.00-------32.80--17.55--
Hongchang International Co Ltd5.42m-208.79k66.15m8.00--1.63--12.21-0.0004-0.00040.01040.07840.09915.5037.20---0.2731-7.98-0.2965-10.944.5111.47-2.76-64.884.64--0.3169--3,289.22---42.63------
Global Pharmatech Inc.3.18m-2.24m67.19m217.00--0.4959--21.13-0.0964-0.09640.13670.34280.22921.593.5714,649.77-16.44---22.55--46.21---71.75--1.62-9.870.2223--32.43---142.03------
CASI Pharmaceuticals Inc22.06m-30.97m70.36m176.00--5.08--3.19-2.23-2.231.591.030.320.92652.03125,312.50-43.04-34.75-66.19-46.9154.3155.98-134.50-153.722.32--0.58---21.41--34.27--14.65--
Rockwell Medical Inc98.92m-1.24m71.10m237.00--2.4449.860.7188-0.0496-0.04963.230.90151.8014.4510.84417,371.30-2.25-46.29-3.34-65.3816.914.66-1.25-36.512.000.31940.2654--14.845.6954.82--76.21--
Journey Medical Corp57.77m-18.34m77.43m58.00--9.87--1.34-0.9276-0.92762.930.52710.8892.166.19996,051.80-28.22---76.21--57.32---31.74--1.03-13.650.6582--7.48--87.00------
I-Mab ADR-100.00bn-100.00bn77.57m220.00--0.33----------2.91-----------35.51---41.43-------509.54----0.00--111.86-13.6544.45---5.95--
Zhong Yuan Bio-Technology Holdings Ltd2.49m232.02k88.37m35.00391.37348.44--35.440.0128-0.01760.13950.01430.8583-1.613.2571,253.436.49--19.10--106.30--7.57--0.83092.530.8593---28.60---148.37------
Assertio Holdings Inc125.76m-68.49m92.07m53.00--0.7056--0.7321-0.7212-0.72121.321.370.38340.90522.342,372,887.00-20.88-21.51-30.33-32.0570.3188.68-54.46-62.101.57--0.2293---2.67-13.38-402.80---28.25--
Scilex Holding Co50.83m-171.53m105.77m113.00------2.08-1.40-1.400.4425-1.770.44015.221.55484,123.80-102.93------68.24---233.88--0.1853-3.72----22.90---614.67------
Procaps Group SA414.10m52.20m125.23m5.50k2.133.181.800.30240.52090.52094.160.34910.8541.873.3875,290.1810.77--19.01--55.04--12.61--0.9861--0.8829--0.0434--142.18------
Data as of Nov 21 2024. Currency figures normalised to Assertio Holdings Inc's reporting currency: US Dollar USD

Institutional shareholders

25.01%Per cent of shares held by top holders
HolderShares% Held
Nantahala Capital Management LLCas of 30 Sep 20248.95m9.39%
The Vanguard Group, Inc.as of 30 Sep 20244.44m4.66%
Renaissance Technologies LLCas of 30 Sep 20243.23m3.39%
BlackRock Fund Advisorsas of 30 Sep 20241.40m1.47%
AQR Capital Management LLCas of 30 Sep 20241.26m1.32%
Millennium Management LLCas of 30 Sep 20241.19m1.24%
Geode Capital Management LLCas of 30 Sep 20241.07m1.13%
Two Sigma Investments LPas of 30 Sep 2024876.04k0.92%
Two Sigma Advisers LPas of 30 Sep 2024745.33k0.78%
Morgan Stanley Smith Barney LLC (Investment Management)as of 30 Sep 2024679.62k0.71%
More ▼
Data from 30 Sep 2024 - 30 Sep 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.